Lyell Immunopharma (LYEL)

• Market cap: $518M
• 1 day: 8.34%
• 5 days: 39.09%
• 1 month: 41.67%
• 3 months: 122.72%
• 6 months: 197.32%
• Year to date: 89.22%
• 1 year: 32.16%
• 5 years: -92.77%
• 10 years: -92.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300